About Us
Founded in 1944, the American Committee for the Weizmann Institute of Science develops philanthropic support for the Weizmann Institute in Israel, and advances its mission of science for the benefit of humanity.
May 31, 2022... REHOVOT, ISRAEL—May 31, 2022—Ketamine, a well-known anesthetic used in smaller doses as a party drug, was hailed as a “new hope for depression” in a Time magazine cover story in 2017. Two years later, the arrival of the first ketamine-based antidepressant – the nasal spray esketamine, made by Johnson & Johnson – was applauded as the most exciting development in the treatment of mood disorders in decades. Yet the U.S. Food and Drug Administration still limits the spray’s use. It is mainly given to depressed patients who have not been helped by other therapies – in part, because the new drug’s mechanism of action is insufficiently understood, leading to concerns over its safety.
Nov 18, 2022... Dr. Sivan Refaely-Abramson of the Molecular Chemistry and Materials Science department at the Weizmann Institute shares a story about sunlight. She explains how, through the amazing world of materials, the power of the sun can transform quantum particles and be used as a main energy source. Dr. Refaely-Abramson’s research in materials science is dedicated to designing intelligent energy conversion in order to consume energy in a way that is clean, green, and unlimited. “Understanding materials and the way particles interact within them allows for new and smart ways to harness sunlight, leading us to a cleaner greener future.”
©2023 American Committee for the Weizmann Institute of Science
FOR THE FOURTH CONSECUTIVE YEAR
